The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
Presentation made by Drs. Charles Driscoll and Ms. Angela Taylor at the live webinar hosted by AlzPossible on the 29th of May, 2014. See recording at http://www.alzpossible.org/wordpress-3.1.4/wordpress/webinars-2/dementia-with-lewy-bodies/
Dementia is a broad term which describes symptoms affecting memory, thinking ability that creates hindrance in performing daily activities. Two important brain functions are badly hit namely- memory and judgement.
Short presentation about dementia, its types, etiologies, pathophysiologies, treatment, and management. It includes information about vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and Alzheimer's Disease.
Presentation delivered by Dr. Carol Manning at the live webinar hosted by AlzPossible at www.alzpossible.org on the 17th of March, 2014.
www.alzpossible.org
topic on dementia covering all aspects regarding classification,pathophysiology and treatment .Difference between MCI and DEMENTIA .best for post graduates ,house officers and medical students
Presentation made by Drs. Charles Driscoll and Ms. Angela Taylor at the live webinar hosted by AlzPossible on the 29th of May, 2014. See recording at http://www.alzpossible.org/wordpress-3.1.4/wordpress/webinars-2/dementia-with-lewy-bodies/
Dementia is a broad term which describes symptoms affecting memory, thinking ability that creates hindrance in performing daily activities. Two important brain functions are badly hit namely- memory and judgement.
Short presentation about dementia, its types, etiologies, pathophysiologies, treatment, and management. It includes information about vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and Alzheimer's Disease.
Presentation delivered by Dr. Carol Manning at the live webinar hosted by AlzPossible at www.alzpossible.org on the 17th of March, 2014.
www.alzpossible.org
topic on dementia covering all aspects regarding classification,pathophysiology and treatment .Difference between MCI and DEMENTIA .best for post graduates ,house officers and medical students
Understand the relation of psychiatry and some common cause of organic brain diseases.
Identify common organic causes of psychiatric presentations
Differentiate dementia and delirium
Principle management of dementia
Identify neuro cognitive domains, differences between major and minor neurocognitive disorders
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
2. Progressive deterioration of intellect, behavior and personality as
a consequence of diffuse disease of the brain hemispheres,
maximally affecting the cerebral cortex and hippocampus.
Dementia is a symptom of disease rather than a single disease
entity!!!
3. Memory must be impaired to make the diagnosis of
dementia.
Loss of memory for recent events is the earlist feature of
dementia.
Subsequent symptoms include abnormal behavior, loss of
intellect, mood changes, and difficulty coping with ordinary
routes.
Insight may be retained initially, but is then usually lost.
Ultimately, there is loss of self-care, wandering,
incontinence, and often paranoia.
4. Dementia has to be distinguished from delirium which is an acute disturbance of
cerebral function with impaired conscious level, hallucinations and autonomic
overactivity as a consequence of toxic, metabolic or infective conditions.
Depression can mimic the initial phases of dementia and it is termed
’pseudodementia’ (which is amenable to antidepressant medication).
5. Dementia may occur at any age but is more common in the elderly,
accounting for 40% of long-term psychiatric in-patients over the age
of 65 years.
The prevalence in persons aged between 50 and 70 years is about
1% and in those approaching 90 years reaches 50%.
An annual incidence rate is 190/100 000 persons.
6. Clinical course:
The rate of progression depends upon the
underlying cause.
The duration of history helps establish the cause of dementia: Alzheimer‘s
disease is slowly progressive over years, whereas encephalitis may be rapid over
weeks.
Dementia due to cerebrovascular disease appears to occur ’stroke by stroke‘.
7.
8. Alzheimer‘s disease (~60% of all dementias)
Cerebrovascular (multiinfarct state, subcortical small
vessel, amyloid angiopathy,…) (~20%)
Neurodegenerative (DLB, Pick‘s disease, Huntington‘s chorea, Parkinson‘s disease)
Infectious (Creutzfeld-Jakob disease, HIV infection, progressive multifocal
leucoencephalopathy)
TREATABLE!
Normal pressure hydrocephalus
Nutritional (thiamine deficiency in alcoholics!, B12 deficiency, folate deficiency)
Metabolic (hepatic disease, thyroid d., parathyroid d., Cushing‘s syndrome)
Chronic inflammatory (MS, …)
Trauma (head injury, ’Punch drunk‘ syndrome)
Tumour (e.g. subfrontal meningioma)
12. Figure 1 Clinicopathological spectrum of neurodegenerative proteinopathies
Elahi, F. M. & Miller, B. L. (2017) A clinicopathological approach to the diagnosis of dementia
Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.96
13.
14. Mild changes in memory and rate of information processing
Not progressive
Does not interfere with daily function or independence
15.
16. Mild cognitive impairment (MCI)
MCI is a relatively recent term, used to describe people who have
some problems with their memory but do not actually have
dementia.
Some people (80%?) will be in the early stages of Alzheimer’s
disease or another dementia. Others, however, will have MCI as a
result of stress, anxiety, depression, physical illness or just an ‘off
day’.
It is estimated that 15% of the population may be experiencing
MCI.
Currently extensive research on MCI is ongoing.
At the moment there is not enough evidence to recommend any
specific treatments.
17. 12% of people over age 70
Usually memory affected
Does not significantly interfere
with daily function
3 times increased risk of
developing AD
10–15% /year will develop
dementia
19. Whole-brain Functional Networks in Cognitively Normal, Mild Cognitive Impairment, and
Alzheimer’s Disease
Eun Hyun Seo, Dong Young Lee, Jong-Min Lee, Jun-Sung Park, Bo Kyung Sohn, Dong Soo Lee ,
Young Min Choe, Jong Inn Woo
Published: January 15, 2013
20. Age
Family hx of AD or Parkinson’s (10-30% risk of AD in
patients with first degree relative)
Head trauma
Depression (early marker for dementia)
Low educational attainment
hyperlipidemia
diabetes
HTN !!!
21. Gender (confounding in literature – women more
likely to live longer, be older….)
Down’s syndrome
22.
23. 1. Memory impairment
2. At least one of the following:
Aphasia
Apraxia
Agnosia
Disturbance in executive functioning
3. Disturbance in 1 and 2 interferes with daily function or
independence
4. Does not occur exclusively during delirium
26. The commonest cause of dementia.
The disorder rarely occurs under the age of 45 years.
The incidence increases with age.
Up to 30% of cases are familial (the loci were found on
chromosome 21 and 19).
Family hx (especially for early types)
Pathology – the presence of senile plaques and neurofibrillary tangles in
the brain.
Diagnosis of AD may be established during life by early
memory failure, slow progression and exclusion of other
causes.
27.
28. Onset usually near age 65; older age, more likely diagnosis
Absence of focal neurological signs (but significant overlap in the
elderly with hx of CVAs…)
Aphasia, apraxia, agnosia
Normal/nonspecific EEG
MRI: bilateral hippocampal atrophy (suggestive)
29. Role of the Hippocampus
Patient HM with surgery for seizures to remove bilateral medial temporal lobes resulting in
severe anterograde amnesia
Formation of new memories
Spatial navigation
Early evidence for damage in this area
30. Depression occurs in 1/3
Delusions and hallucinations in 1/3
Extracellular deposition of amyloid-beta protein, intracellular
neurofibrillary tangles, and loss of neurons at autopsy
Clinical diagnosis: 87% of diagnosed AD confirmed pathologically
(but high pretest probability increases predictive value of clinical
diagnosis!!!)
31.
32.
33. This is an overdiagnosed condition which accounts for less than 10% of cases
of dementia.
MID is caused by multiple strokes - SILENT STROKES
Dementia occurs ’stroke by stroke‘, with progressive focal loss of function.
Clinical features of stroke profile – hypertension, diabetes, etc. – are present.
More often in males.
Diagnosis is obtained from the history and
confirmed by CT or MRI scan (the presence
of multiple areas of infarction).
Treatment: Maintain adequate blood pressure control,
anti-platelet aggregants (aspirin).
34.
35.
36. Onset of cognitive deficits associated with a stroke (but often no
clear hx of CVA but multiple small, undiagnosed CVAs)
Abrupt onset of symptoms with stepwise deterioration
+Findings on neurological examination
Infarcts on cerebral imaging (but ct/mri findings often have no clear
relationship)
37. Most patients previously categorized as either Alzheimer’s type or
vascular type dementias probably have BOTH
Likelihood of AD and vascular disease significantly increases with
age, therefore likelihood of both does as well
Vascular risk factors predispose to AD -- ?does it allow the
symptoms of AD to be unmasked earlier??
38. 30% with PD may develop dementia; Risk Factors:
Age over 70
Depression
Confusion/psychosis on levodopa
Facial masking upon presentation
Hallucinations and delusions
May be exacerbated by treatment
Usually occurs 10 y after the PD onset
39.
40. Dementia with Lewy bodies (DLB)
One of the most common types of progressive dementia.
Progressive cognitive decline, combined with three additional defining
features:
(1) pronounced “fluctuations” in alertness and attention;
(2) recurrent visual hallucinations,
(3) parkinsonian motor symptoms, such as rigidity and the loss of
spontaneous movement.
41. The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-
synuclein protein - inside the nuclei of neurons in areas of the brain that control particular
aspects of memory and motor control. Lewy bodies are often also found in the brains of people
with Parkinson's and Alzheimer’s diseases.These findings suggest that either DLB is related to
these other causes of dementia or that an individual can have both diseases at the same time.
DLB usually occurs sporadically, in people with no known family history of the disease.
However, rare familial cases have occasionally been reported.
42.
43.
44. Cortical Lewy Bodies on path
10–20% of dementias
Compare to PD: Lewy Bodies in substantia nigra
Overlap with AD and PD
40% patients with AD have LBs on path
46. Visual hallucinations
2/3 of patients with DLB
Rare in AD
May precede other symptoms of DLB
Psychosis, paranoia and other psychiatric
manifestations early in course
Cognitive Fluctuations
60–80%
Episodic
Loss of consciousness, staring spells, more
confused or delirious like behavior
Days of long naps
Significant impact on functional status
47. Parkinsonism
70–90%
More bilateral and symmetric than with PD
Tremor less common
Bradykinesia, rigidity, gait changes
Sleep disorders
REM sleep behavior disorder/parasomnia
Acting out of dreams: REM dreams
without usual muscle atonia
85% of patients with DLB
May precede other symptoms by years
48. More progressive course than AD or Vascular dementia
Possibly better response to cholinergic drugs than AD or vascular dementias
?response of psychiatric type symptoms to cholinergic agents/cholinesterase inhibitors
DLB: Neuroleptic Hypersensitivity
30–50% of patients
May induce Parkinsonian symptoms or cognitive changes that are not reversible, leading to
rapid decline in overall status
NOT dose related
Slightly less likely with newer atypical antipsychotics, but can STILL happen
49. This progressive condition accounts for 5% of all dementias.
Usually sporadic, it more commonly affect women between 40 and 60 years.
Personality and behaviour are initially more affected than memory.
Frontal lobe dysfunction predominates with apathy, lack of initiative and personality changes.
CT or MRI scans show frontal (and/or temporal) atrophy, often asymmetrical.
SPECT reveal anterior hypoperfusion, EEG is usually normal.
The disorder is characterized pathologically by argyrophylic inclusion bodies within the
cytoplasm of cells of the frontotemporal cortex.
There is no treatment, death occuring within 2-3 years of the onset.
50. Impairment of executive function
Initiation
Goal setting
Planning
Disinhibited/inappropriate behavior (90%)
Cognitive testing may be normal; memory loss NOT prominent early
feature
5–10% cases of dementia
Onset usually 45–65 (rare after age 75)
Familial: 20–40%
51. This condition is one of a group of disorders characterized
by asymmetrical cortical degeneration.
Dominant hemisphere perisylvian atrophy is associated with
loss of language, which, after many years, becomes a more
widespread dementia.
Pathologically non-specific cell loss, Pick’s pathology or
spongiform changes are described.
MRI and SPECT confirm focal changes.
52. Uncommon
Vertical supranuclear palsy with downward gaze abnormalities
Postural instability
Falls (especially with stairs)
“Surprised look”
Difficulty with spilling food/drink
53. Subtype of frontal lobe dementia
Pick bodies (silver staining intracytoplasmic inclusions in
neocortex and hippocampus)
?Serotonergic deficit?
Language abnormalities and behavioral disturbances
Logorrhea (abundant unfocused speech)
Echolalia (spontaneous repetition of words/phrases)
Palilalia (compulsive repetition of phrases)
Fluent or non-fluent forms
54. Patients slowly develop non-fluent, anomic aphasia with hesitant,
effortful speech
Repetition, reading, writing also impaired; comprehension initially
preserved
Slow progression, initially memory preserved but 75% eventually
develop non-language deficits; most patients eventually become
mute
Average age of onset = 60
Subset of FTD
55. = term applied to the triad of:
1. Dementia
2. Gait disturbance
3. Urinary incontinence
occuring in conjunction with hydrocephalus and normal CSF pressure.
Two types:
- NPH with a preceding cause (SAH, meningitis, trauma,
radiation-induced).
- NPH with no known preceding cause – idiopathic (50%).
56. Aetiology is unclear.
It is presumed that at some preceding period, impedence to normal CSF
flow causes raised intraventricular pressure and ventricular dilatation.
Compensatory mechanisms permit a reduction in CSF pressure yet the
ventricular dilatation persists and causes symptoms.
57. Diagnosis is based on clinical picture plus CT scan/MRI evidence of ventricular enlargement.
NPH must be differentiated from pts whose ventricular enlargement is merely the result of
shrinkage of the surrounding brain, e.g. AD. These pts do not respond to CSF shunting,
whereas a proportion of NPH pts (but not all) show a definitive improvement with ventriculo-
peritoneal shunting.
58. Gait
Early Feature
Most responsive to shunting
Magnetic/gait apraxia/frontal “ataxia”
Cognitive
Psychomotor slowing, apathy, decreased attention
Urinary
Urgency or incontinence
59. Hydrocephalus in absence of papilledema, with normal CSF
pressure
Begins as transient/intermittent increased CSF pressure, leading to
ventricular enlargement; ventricular enlargement leads to
normalization of CSF pressure
Thought to be due to decreased CSF absorption at arachnoid villi
Causes: SAH, tumors, CVA
60. Diagnosis: initially on neuroimaging
Ventricular enlargement our of proportion to sulcal
atrophy
Miller Fisher test: objective gait assessment before
and after removal of 30 cc CSF
Radioisotope diffusion studies of CSF
MRI: turbulent flow in posterior third ventricle and
within aqueduct of sylvius
MRI flow imaging
SPECT (Single Photon emission CT): decreased
blood flow in frontal and periventricular areas
61. Limited data
Gait may be most responsive
Predictors of better outcome:
Lack of significant dementia
Known etiology (prior SAH)
New (< 6 months) symptoms
Prominence of gait abnormality
62. Approximately two-thirds of persons with AIDS develop
dementia, mostly due to AIDS dementia complex.
In some patients HIV is found in the CNS at postmortem. In
others an immune mechanism or an unidentified pathogen is
blamed.
Dementia is initially of a "subcortical " type.
CT - atrophy; MRI - increased T2 signal from white matter.
Treatment with Zidovudine (AZT) halts and partially revers
neuropsychological deficit.
63. Reduction of intellectual function is common after severe head injury.
Chronic subdural haematoma can also present as progressive dementia,
especially in the elderly.
Punch-drunk encephalopathy (dementia pugilistica) is the cumulative result of
repeated cerebral trauma. It occurs in both amateur and professional boxers and
it manifests by dysarthria, ataxia and expy signs associated with ’subcortical‘
dementia. There is no treatment for this progressive syndrome.
64. Dementia rarely may be due to intracranial tumour, especially when tumours
occur in certain anatomical sites.
Mental or behavioral changes occur in 50-70% of all brain tumours as distinct
from dementia which is associated with frontal lobe tumours, III ventricle
tumours and corpus callosum tumours.
Cognitive impairment also occurs as a non metastatic complication of systemic
malignancy.
65. Rapid onset and deterioration
Motor deficits
Seizures
Slowing and periodic complexes on EEG
Myotonic activity
72. Investigation
Blood tests (to exclude hypothyroidism,FBS, Lipid profile ,
vitamin B12, thiamine and folate deficiency, Lyme disease, HIV
infection, metabolic disorders and inflammatory diseases).
Liver and renal function
Lumbar puncture
ECG , Echocardiogram
CRP, ESR
Serum Na,K, Ca
Cranial imaging (CT or/and MRI) (to exclude NPH)
PET and SPECT
EEG (slowing in AD, normal in pseudodementia, periodic
complexes in CJD)
Genetic testing (rarely – Huntington mutation, apolipoprotein E4
mutation in AD)
Brain biopsy (if treatable cause is suspected)
73. schematic approach to history taking and involving clinical history assessments that assay
cognition, function abilities, and behavior.
An informant generally provides these data components due to the limited reliability of a
patient with impaired memory and insight
74.
75. The Ascertain Dementia 8 (AD8), an 8-item measure of informant-reported changes
in cognitive functioning, is a well-validated and widely used historical cognitive
screening instrument
The AD8 content includes memory, orientation, and other faculties, including
executive, motivation, praxis, and functional ability(eg,managing money).
A score of 2 or higher (out of 8 total items) on the AD8 is highly predictive of
dementia
76.
77. MENTAL STATUS EXAMINATION
The mental status examination is the part of the neurologic examination that assesses current mental
capacity through evaluation of appearance, mood, perceptions (eg, delusions, hallucinations), and all
aspects of cognition (eg, attention, orientation, memory).
Several standardized mental status examinations enable quantification of cognitive impairment,
typically yielding a single composite score that reflects disease severity. For example, the Montreal
Cognitive Assessment, a brief 30-point screening instrument, was developed and
validated to identify patients with mild cognitive impairment, a clinical state that often progresses to
dementia.
78. 24/30 suggestive of dementia (sens 87%, spec 82%)
Not sensitive for MCI
Spuriously low in people with low educational level, low SES, poor language skills,
illiteracy, impaired vision
Not sensitive in people with higher educational background
79. No on serial sevens (months backwards, name backwards…
assessment of attention)
Assess literacy prior
Assess for dominant hand prior to handing paper over
Do not over lead
3-item repetition, repeat all 3 then have patients repeat; 3-stage
command, repeat all 3 parts of command and then have patient
do…
80. Clockface
Short assessments with good validity: 3-item recall and clockface
Neurological exam (focality, frontal release signs such as grasp, jawjerk;
apraxia, cogwheeling, eye movements)
Lab testing and neuroimaging
81. • Tests such as the MMSE, however, are not particularly sensitive indicators of
early disease manifestations. Therefore, in some instances, the behavioral
neurologist will need to assess skills such as episodic memory, working memory,
executive functions, language, and visuospatial abilities in greater detail
• The Perhaps the most widely used measure in behavioral neurology
and dementia is the Mini-Mental State Examination (MMSE).Typically
taking about 10 minutes.
• The MMSE evaluates orientation to time and place, registration,a
ttention, working memory, recall, language, and visuoconstruction. This
30- point scale was originally designed to facilitate differential diagnosis
of hospitalized psychiatric patients but is now routinely used to assess
cognitive abilities in a broad range of diagnoses
89. Working memory is a functional system that works
to register, recall, and mentally manipulate information within short-term
memory and it is a common substrate to patients’ difficulty with
multitasking.
Digit span tests are widely used, with the forward digit span component
used to assess immediate auditory memory, and the backward span
component evaluating working memory (ie, the capacity to juggle
information mentally). Research has shown that on average, people
can keep 7 ± 2 items in their short term memory.
Working memory is assessed on MMSE when the patient spells world
backward.
Reciting months of the year in reverse.
90. Mental flexibility:
The Trail Making Test is a widely administered test of attention and
cognitive flexibility.
In Part A of the test, patients connect a series ofnumbered circles
distributed arbitrarily on a page.
In Part B, the patients are to serially alternate between connecting
numbers and letters (eg, 1 to A to 2 to B, etc) that also are arranged
arbitrarily on a page. The scores are the time taken to complete each part.
This test is particularly sensitive to the progressive cognitive
decline in dementia. Elderly persons who perform poorly on Part B are
likely to have problems with complex activities of daily living.
91. Inhibition:
Response inhibition requires the patient to suppress an overlearned
response or a salient environmental stimulus.
Stroop interference tests are widely used to assess inhibition. In
this paradigm, patients are shown a series of color names printed in
a dissonant color of ink (eg, the word red printed in blue ink). The
patient has to inhibit the overlearned tendency to read the words
and instead name the color of the ink in which the words are printed.
92. Fluency:
can be assessed by having the patient generate words beginning with
specified letters (eg, F-A-S) or belonging to semantic categories (eg,
animals) in a specified time period, usually 1 minute for each letter or
category.
Relative difficulty with semantic categories often suggests AV or SV,
whereas relative difficulty with letter prompts (phonemic cueing) suggests
frontal and/or subcortical deficits.
Nonverbal fluency tasks eg, design fluency) typically present patients with
numerous boxes containing dots and require them to generate as many
novel designs as possible by connecting the dots following specified rules.
93. Abstract reasoning:
Abstract reasoning can be evaluated by asking patients to describe
conceptual similarities or differences between word pairs (eg, dog—
lion), give opposites (eg, healthy— sick), or interpret proverbs .
When asked to describe how a dog and a lion are alike, a patient
with poor abstract reasoning might provide a very concrete answer,
such as they both have four legs, fur, or a tail; a more correct,
conceptual response is that they are both animals or mammals.
For interpreting proverbs, the patient should describe the essence
or meaning of the proverb. A patient with EF Problems often
provides a rather concrete response.
94. • Several aspects of language should be screened during
neurocognitive testing, including articulatory agility, repetition of
high-frequency and low-frequency word combinations (eg, ‘‘No
ifs, ands, or buts,’’ )
• comprehension of single words (give the subject simple
commands, such as, ‘‘Show me your chin,’’ or have the patient
say the word that a picture is illustrating), comprehension of
complex syntax (eg, ‘‘Put your left hand on your right ear”,
reading of regular and irregular words and naming (the Boston
naming test).
• Reading and writing should also be assessed.
Language:
95. Visuospatial Abilities:
Constructional tasks are extremely useful in detecting organic brain disease and should be included
in every neurocognitive assessment.
Constructional abilities require complex nonverbal cognitive functions and rely on a multifaceted
network of brain regions, including parietal, frontal, and occipital cortex.
Parietal cortex in particular is critical for the integration of visual/spatial information.
Design copying (eg, interlocking pentagons or hexagons, cube, clock, Rey-Osterrieth complex
figure, or modified Rey-Osterrieth complex figure is commonly used to examine visuoconstructional
abilities at the bedside.
Careful observation of how patients approach their copy can be an extremely useful part of the
evaluation. For example, working from right to left, omitting parts of the left side , directional
confusion and missing the overall configuration ,all could point out to right hemisphere injury
Another useful test for neglect, and one that may help differentiate it from a visual-field defect, is to
show patients a page with the letter C drawn in various orientations and ask them to complete the
C into an O.
96.
97.
98. Functional status refers to the capacity to carry out instrumental
activities of daily living, such as food preparation, medication
management, driving, housekeeping, financial management, and
shopping.
It can be informally assessed by asking patients if they are
having difficulty carrying out these daily activities.
Functional abilities can also be assessed by having caregivers
complete questionnaires, such as the Functional Activities
Questionnaire and the Clinical Dementia Rating scale
Components of the neurocognitive assessment that bear the
strongest relationship to functional abilities are memory and EF.
99. Depression anxiety psychosis common
Apathy agitation disinhibition typical for dementia and traumatic brain injury
Mood pseudodementia
Assessment of depression
100.
101.
102.
103.
104.
105. Cholinesterase inhibitor
1 systematic review with 5 RCTs, 1434 people, 1–39 weeks
No difference in overall clinical improvement
Some clinically insignificant improvement in cognition
Significant risk of LFT abnormalities: NOT USED
106. Aricept
Cholinesterse inhibitor
Easy titration (start 5/day, then 10)
Side effects: GI (nausea, diarrhea)
Can be associated with bradycardia
Main effect seems to be lessening of rate of decline, delayed time to needing nursing
home/more intensive care
107. NEJM April 2003
Moderate to severe AD (MMSE 3–14)
N-methyl D aspartate (NMDA) receptor antagonist; theory that
overstimulation of NMDA receptor by glutamate leads to
progressive neurodegenerative damage
28-week, double blinded, placebo controlled study; 126 in each
group; 67% female, mean age 76, mean MMSE 7.9
108. Found less decline in ADL scores, less decline in MMSE (-.5 instead of –1.2)
Problem: significant drop outs (overall 28% dropout rate) in both groups; data analyzed did
not account for drop outs, followed those “at risk”
109. Rivastigmine
Galantamine
Cholinesterase inhibitors
?more side effects, more titration required
Future directions:
Prevention of delirium in at-risk patients (cholinergic theory of delirium)
Behavioral effects in those with severe dementia?
Treatment of Lewy Body dementia
Treatment of mixed Vascular/AD dementia
110. Unclear benefit
Less than 10mg day, selective MAO B inhibitor
Small studies, not very conclusive
111. NEJM 1997: selegiline, Vit E, both , placebo for tx of AD
Double blind, placebo controlled, RCT with mod AD; 341
patients
Primary outcome: time to death, institutionalization, loss of
ADLS, severe dementia
Baseline MMSE higher in placebo group
No difference in Primary outcomes; adjusted for MMSE
differences at baseline and found delay in time to NH from
670 days with Vit E to 440 days with placebo
112. 1 systematic review of 9 double blind RCTs with AD, vascular, or mixed dementia
Heterogeneity, short durations
High withdrawal rates; best studies have shown no significant change in clinician’s global
impression scores
NO good evidence to support estrogens or NSAIDS
114. HTN and DM linked to ALL types dementia
Studies of treating systolic hypertension in the elderly
(SHEPS and others): decreased risk of development of
cognitive impairment in patients in treatment group
Decreased risk included vascular AND Alzheimer type
dementias
Cholinesterase inhibitors seem to work as well (or as poorly)
for both vascular and Alzheimer type of dementias
What is the link? Both common, ?unmasking?
115. Conflicting data
Retrospective studies suggest decreased risk in those patients who are treated with statins
PROSPER study
6000 patients age 70–80 with vascular risk factors given pravastatin or placebo
3 year: no effect on cognitive function
?Long enough follow up?
116. Delirium Treat underlying medical condition, If medication is needed, consider typical antipsychoc.
Depression
Without psychosis: antidepressant With psychosis: antidepressant plus antipsychotic, or ECT
Psychosis
Acute: atypical antipsychotic Long-term: atypical antipsychotic
Anxiety
Acute: benzodiazepine such as lorazepam or oxazepam Long-term: buspirone
Insomnia
Acute: trazodone ,consider or zolpidem Long-trm: trazodone
“Sundowning”
Acute: trazodone Long-term: trazodone; typical or atypical antipsychotic.
Aggression or anger
Severe Acute: typical or atypical antipsychotic
Long-term: divalproex sodium (Depakote) or atypical antipsychotic
Mild Acute: trazodone
Long-term: divalproex sodium, SSRI, trazodone, or buspirone
Osteoarthritic pain Long-term: tricyclic antidepressant, SSRI, or trazodone
117.
118. Antipsychotic drugs
Haloperidol (Haldol), fluphenazine ,thiothixene, Trifluoperazine (Stelazine)
Dosage: varies by agent
Comments: anticipated extrapyramidal symptoms; if these symptoms occur, decrease
dosage or switch to another agent;
be cautious with the use of benztropine (Cogentin) or trihexyphenidyl (Artane).
119. Atypical antipsychotic agents
Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation,
and combativeness
General cautions: diminished risk of developing extrapyramidal symptoms and tardive dyskinesia
compared with typical antipsychotic agents
Risperidone (Risperdal)
Initial dosage: 0.25 mg per day at bedtime; maximum: 2 to 3 mg per day, usually twice daily in
divided doses
Olanzapine (Zyprexa)
Initial dosage: 2.5 mg per day at bedtime; maximum: 10 mg per day, usually twice daily in divided
doses
Quetiapine (Seroquel)
Initial dosage: 12.5 mg twice daily; maximum: 200 mg twice daily
120. Risperidone (0.5 BID)
Olanzepine (zyprexa): 2.5–5 mg/day
Quetiapine (seroquel)
Rapid titration, use in PD
12.5–200 mg/day
Clozapine
Use in PD (least risk of tremor)
Agranulocytosis and limited use
Ziprasidone (geodon)
QT prolongation
121. Side Effects:
Sedation
Anticholinergic effects
Prolonged QT
Edema
Orthostasis
Weight gain
Confusion
Warnings:
FDA black box warning for increased mortality (OR 1.5–1.7), and increased
?increased stroke risk
122. Mood-stabilizing (antiagitation)
drugs
Recommended uses: control of problematic delusions, hallucinations, severe
psychomotor agitation, and combativeness; useful alternatives to antipsychotic agents
for control of severe agitated, repetitive, and combative behaviors
Carbamazepine (Tegretol)
Initial dosage: 100 mg twice daily; titrate to therapeutic blood level (4 to 8 mcg per mL)
Comments: monitor complete blood cell count and liver enzyme levels regularly;
carbamazepine has problematic side effects.
Divalproex sodium (Depakote)
Initial dosage: 125 mg twice daily; titrate to therapeutic blood level (40 to 90 mcg per
mL)
Comments: generally better tolerated than other mood stabilizers; monitor liver enzyme
levels; monitor platelets, prothrombin time, and partial thromboplastin time as
indicated.
123. Anixolytic medications
Benzodiazepines
Recommended uses: management of insomnia, anxiety, and agitation
General cautions: regular use can lead to tolerance, addiction, depression, and cognitive
impairment; paradoxic agitation occurs in about 10% of patients treated with
benzodiazepines; infrequent, low doses of agents with a short half-life are least
problematic.
Lorazepam (Ativan), oxazepam (Serax), temazepam (Restoril), zolpidem (Ambien),
triazolam (Halcion)
Nonbenzodiazepines
Buspirone (BuSpar)
Initial dosage: 5 mg twice daily; maximum: 20 mg three times daily
Comments: useful only in patients with mild to moderate agitation; may take 2 to 4
weeks to become effectiv
124. Antidepressant drugs
General cautions: selection of an antidepressant is usually based on previous
treatment response, tolerance, and the advantage of potential side effects (e.g.,
sedation versus activation);
a full therapeutic trial requires at least 4 to 8 weeks; as a rule, dosage is increased
using increments of initial dose every 5 to 7 days until therapeutic benefits or
significant side effects become apparent; after 9 months, dosage reduction is used
to reassess the need to medicate; discontinuing an antidepressant over 10 to 14
days limits withdrawal symptoms.
NOTE: Patients with depression and psychosis require concomitant antipsychotic
medication.
125. Desipramine (Norpramin)
Initial dosage: 10 t 25 mg in the morning; maximum: 150 mg in the morning
Comments: tends to be activating (i.e., reduces apathy); lower risk for cardiotoxic,
hypotensive, and anticholinergic effects; may cause tachycardia; blood levels may be
helpful-
Nortriptyline (Pamelor) desipramine,
Initial dosage: 10 mg at bedtime; anticipated dosage range: 10 to 40 mg per day (given
twice daily)
Comments: tolerance profile is similar to that for but nortriptyline tends to be more
sedating; may be useful in patients with agitated depression and insomnia; therapeutic
blood level “window” of 50 to 150 ng per mL (190 to 570 nmol per L)
126. Nefazodone (Serzone)
Initial dosage: 50 mg twice daily; maximum: 150 to 300 mg twice daily
Comments: effective, especially in patients with associated anxiety; reduce dose of
coadministered alprazolam (Xanax) or triazolam by 50%; monitor for hepatotoxicity.
Bupropion (Wellbutrin)
Initial dosage: 37.5 mg every morning, then increase by 37.5 every 3 days; maximum:
150 mg twice daily
Comments: activating; possible rapid improvement of energy level; should not be used
in agitated patients and those with seizure disorders; to minimize risk of insomnia, give
second dose before 3 p.m.
Mirtazapine (Remeron)
Initial dosage: 7.5 mg at bedtime; maximum: 30 mg at bedtime
Comments: potent and well tolerated; promotes sleep, appetite, and weight gain
127. .
Fuoxetine (Prozac)
Initial dosage: 10 mg every other morning; maximum: 20 mg every morning
Paroxetine (Paxil)
Initial dosage: 10 mg per day; maximum: 40 mg per day (morning or evening)
Comments: less activating but more anticholinergic than other SSRIs
Sertraline (Zoloft)
Initial dosage: 25 to 50 mg per day; maximum: 200 mg per day (morning or evening)
Comments: well tolerated; compared with other SSRIs, sertraline has less effect on metabolism of other medications.
Citalopram (Celexa)
Initial dosage: 10 mg per day; maximum: 40 mg per day
Comments: well tolerated; some patients experience nausea and sleep disturbances.
Fluvoxamine (Luvox)
Initial dosage: 50 mg twice daily; maximum: 150 mg twice daily
Comments: exercise caution when using fluvoxamine with alprazolam or triazolam.
Venlafaxine (Effexor)
Initial dosage: 37.5 mg twice daily; maximum: 225 mg per day in divided doses
128. Lithium
Recommended uses: for anticycling; can also be used to augment antidepressant drugs
General cautions: at higher lithium dosages, elderly patients are prone to develop neurotoxicity.
Initial dosage: 150 mg per day
Comments: blood levels of 0.2 to 0.6 mEq per L (0.2 to0.6 mmol per L) are generally adequate and
are usuallyachieved with dosage of 150 to 300 mg per day.
Electroconvulsive therapy
Recommended uses: may be required in patients who are at risk of injuring or starving themselves,
patients who are severely psychotic, and patients who cannot tolerate or do not respond to antide
pressants